In Brief: Boehringer Ingelheim Micardis
Executive Summary
Boehringer Ingelheim Micardis: Marketing rights for telmisartan outside the U.S., Japan and "certain other countries" are assigned to Glaxo Wellcome. Glaxo and BI will jointly perform ongoing clinical research with the angiotensin II inhibitor. BI will market Micardis in the U.S. The company filed a telmisartan NDA for hypertension Sept. 27, 1997...